MacroGenics advances MGC026 in Phase 1 study for squamous cell carcinoma of the head and neck
MacroGenics reports success in the Phase 1 Stage 1 cohort of MGC026 for squamous cell carcinoma of the head and neck and announced clinical trial poster presentations at ESMO 2026.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day